Nivedita Findlay

Wool Equities Ltd. develops, manufactures and distributes wool products. It has retail and distribution access in the U.S. The company was founded on August 29, 1997 and is headquartered in Palmerston North, New Zealand.

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Part of Genesis Research & Development Corp. Ltd., BioStore NZ Ltd. operates a pharmaceutical company. The company is based in Auckland, New Zealand.

Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London.

CoDa Therapeutics (NZ) Ltd. develops and markets biopharmaceutical products. The company was founded by David Becker, Colin Green, Bradford J, Duft, and Howard E. Greene and on December 9, 2003 and is headquartered in Auckland, New Zealand.

Minomic International Ltd. develops diagnostic and imaging products for prostate cancer and diabetes. Its MiCheck test detects a protein that is present on cancer cells by using blood sample. The company was founded in 1974 and is headquartered in Sydney, Australia.

Part of AgResearch Ltd., Orico Ltd. engages in the research and development of biotechnology and muscle growth therapeutics in livestock. The company is based in Dunedin, New Zealand.

Part of AgResearch Ltd., Paraco Ltd. engages in the research and development of parasite technology for sheep. The company is based in Hamilton, New Zealand. Paraco was acquired by AgResearch Ltd. on August 05, 2008.

Biocomm Square Pty Ltd. provides business development and licensing consulting services. The firm provides business development and licensing, corporate strategy, business planning, project management and portfolio review and technology assessment services. It also offers services like market analysis, competitive intelligence, scientific and commercial evaluation and assessment, in and out licensing strategy development, arrangement and implementation, research collaboration and alliances, biotechnology, biopharmaceuticals and cellular therapeutics services. The company was founded by Andrew John Hubert Gearing and Tsutomu Mori in 2007 and is headquartered in Clayton, Australia.

EnCoate Holdings Ltd. develops food-grade biopolymer technologies. The company was founded in 2003 and is headquartered in Lincoln, New Zealand.

Biomatters Ltd. engages in the design of bioinformatics software for molecular biologists and biochemists. It specializes in software development, biotechnology, bioinformatics, sequence analysis, next-generation sequencing, genomics, DNA sequence alignment, assembly and analysis. The firm's products include Geneious, Genome and Melanoma. The company was founded by Daniel Batten, Alexei J. Drummond, Athena Ferreira and Julio Ferreira in 2003 and is headquartered in Auckland, New Zealand.

Keraplast Manufacturing provides personal care products in nutritional and medical areas. It builds blocks at a cellular level, giving the human body structure and order and also develops healthy tissues, including skin, hair and nails. The company is headquartered in Lincoln, New Zealand.

Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia.

Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands.

CuroNZ Ltd. is a clinical stage neurotherapeutics company based in Wellsford, New Zealand. The New Zealander company's vision is to transform the quality of life for severely neurologically affected children and adult patients. CuroNZ Ltd. focuses on developing a body and mind boosting drug therapy using a modified naturally occurring molecule called nrp2945. This molecule controls seizure activity and improves comorbidities in patients diagnosed with epileptic encephalopathy syndromes like Lennox-Gastaut syndrome and drug-resistant temporal lobe epilepsy. CuroNZ's peptide drug, nrp2945, has a minimal adverse event profile and is administered through subcutaneous injections every other day. The company has conducted successful phase I safety trials in healthy volunteers and a small phase II trial in patients with absence epilepsy.

Part of Firefly Health, Inc., Firefly Health Pty Ltd. is an Australian healthcare company that provides resources and tips for healthcare providers who treat Firefly Health members. The company is based in South Melbourne, Australia. The company aims to make the healthcare process easier for providers and lower healthcare costs for employees. The company was founded in 2012 and the CEO is Fay Rotenberg.

Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA.

Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.

Stablix, Inc. is a biotechnology company based in New York, NY. The company is focused on establishing a new paradigm for tackling diverse diseases by harnessing the power of the body's own cellular machinery through targeted protein stabilization. Stablix's restored™ platform generates heterobifunctional small molecules (restoracs™) that selectively recruit active deubiquitinases (dubs) to target proteins for precise removal of ubiquitin to restore protein function. The company is currently advancing its lead programs towards clinical studies. The company's platform is based on the work of Henry Colecraft, Ph.D., professor of physiology and cellular biophysics, and professor of pharmacology, Columbia University Irving Medical Center. Stablix was founded in June 2021 with a $63 million series A led by founding investor Versant Ventures with New Enterprise Associates (NEA), Cormorant Asset Management, Euclidean Capital, and Alexandria Venture Investments. Stuart Anthony Kingsley has been the CEO of the company since 2022.